Literature DB >> 27106041

Context-dependent effects of SOCS3 in angiotensin II-induced vascular dysfunction and hypertension in mice: mechanisms and role of bone marrow-derived cells.

Ying Li1, Dale A Kinzenbaw2, Mary L Modrick2, Lecia L Pewe3, Frank M Faraci4.   

Abstract

Carotid artery disease is a major contributor to stroke and cognitive deficits. Angiotensin II (Ang II) promotes vascular dysfunction and disease through mechanisms that include the IL-6/STAT3 pathway. Here, we investigated the importance of suppressor of cytokine signaling 3 (SOCS3) in models of Ang II-induced vascular dysfunction. We examined direct effects of Ang II on carotid arteries from SOCS3-deficient (SOCS3(+/-)) mice and wild-type (WT) littermates using organ culture and then tested endothelial function with acetylcholine (ACh). A low concentration of Ang II (1 nmol/l) did not affect ACh-induced vasodilation in WT but reduced that of SOCS3(+/-) mice by ∼50% (P < 0.05). In relation to mechanisms, effects of Ang II in SOCS3(+/-) mice were prevented by inhibitors of STAT3, IL-6, NF-κB, or superoxide. Systemic Ang II (1.4 mg/kg per day for 14 days) also reduced vasodilation to ACh in WT. Surprisingly, SOCS3 deficiency prevented most of the endothelial dysfunction. To examine potential underlying mechanisms, we performed bone marrow transplantation. WT mice reconstituted with SOCS3(+/-) bone marrow were protected from Ang II-induced endothelial dysfunction, whereas reconstitution of SOCS3(+/-) mice with WT bone marrow exacerbated Ang II-induced effects. The SOCS3 genotype of bone marrow-derived cells did not influence direct effects of Ang II on vascular function. These data provide new mechanistic insight into the influence of SOCS3 on the vasculature, including divergent effects depending on the source of Ang II. Bone marrow-derived cells deficient in SOCS3 protect against systemic Ang II-induced vascular dysfunction.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  carotid artery disease; cerebral arteries; endothelial dysfunction; endothelium; suppressor of cytokine signaling 3

Mesh:

Substances:

Year:  2016        PMID: 27106041      PMCID: PMC4967211          DOI: 10.1152/ajpheart.00204.2016

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  58 in total

1.  Responses of carotid artery in mice deficient in expression of the gene for endothelial NO synthase.

Authors:  F M Faraci; C D Sigmund; E G Shesely; N Maeda; D D Heistad
Journal:  Am J Physiol       Date:  1998-02

2.  Cerebral vascular effects of angiotensin II: new insights from genetic models.

Authors:  Frank M Faraci; Kathryn G Lamping; Mary L Modrick; Michael J Ryan; Curt D Sigmund; Sean P Didion
Journal:  J Cereb Blood Flow Metab       Date:  2006-04       Impact factor: 6.200

3.  Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis.

Authors:  T Shouda; T Yoshida; T Hanada; T Wakioka; M Oishi; K Miyoshi; S Komiya; K Kosai; Y Hanakawa; K Hashimoto; K Nagata; A Yoshimura
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

4.  Critical role for CuZn-superoxide dismutase in preventing angiotensin II-induced endothelial dysfunction.

Authors:  Sean P Didion; Dale A Kinzenbaw; Frank M Faraci
Journal:  Hypertension       Date:  2005-10-10       Impact factor: 10.190

5.  Increased superoxide and vascular dysfunction in CuZnSOD-deficient mice.

Authors:  Sean P Didion; Michael J Ryan; Lisa A Didion; Pamela E Fegan; Curt D Sigmund; Frank M Faraci
Journal:  Circ Res       Date:  2002-11-15       Impact factor: 17.367

6.  Angiotensin II activates nuclear transcription factor-kappaB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice.

Authors:  M Ruiz-Ortega; O Lorenzo; M Rupérez; Y Suzuki; J Egido
Journal:  Nephrol Dial Transplant       Date:  2001       Impact factor: 5.992

7.  Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II.

Authors:  P J Pagano; J K Clark; M E Cifuentes-Pagano; S M Clark; G M Callis; M T Quinn
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

8.  A mouse model of angiotensin II slow pressor response: role of oxidative stress.

Authors:  Noritaka Kawada; Enyu Imai; Alexsander Karber; William J Welch; Christopher S Wilcox
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

9.  PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.

Authors:  Michael J Ryan; Sean P Didion; Satya Mathur; Frank M Faraci; Curt D Sigmund
Journal:  Hypertension       Date:  2004-01-26       Impact factor: 10.190

10.  Small-molecule inhibitors of signal transducer and activator of transcription 3 protect against angiotensin II-induced vascular dysfunction and hypertension.

Authors:  Andrew W Johnson; Dale A Kinzenbaw; Mary L Modrick; Frank M Faraci
Journal:  Hypertension       Date:  2012-12-24       Impact factor: 10.190

View more
  10 in total

1.  Bone Marrow-Derived Tenascin-C Attenuates Cardiac Hypertrophy by Controlling Inflammation.

Authors:  Lei Song; Lai Wang; Fuqiang Li; Ada Yukht; Minghui Qin; Haley Ruther; Mingjie Yang; Aurelio Chaux; Prediman K Shah; Behrooz G Sharifi
Journal:  J Am Coll Cardiol       Date:  2017-09-26       Impact factor: 24.094

2.  Clinical Values and Underlying Mechanism Analysis of Serum miR-455-5p in Carotid Artery Stenosis.

Authors:  Bin Zhu; Wei Liu; Qiang Xu; Hong-Liang Liu
Journal:  J Inflamm Res       Date:  2022-05-30

3.  Angiotensin II-induced endothelial dysfunction: Impact of sex, genetic background, and rho kinase.

Authors:  Dale A Kinzenbaw; Lucy Langmack; Frank M Faraci
Journal:  Physiol Rep       Date:  2022-06

4.  Is Hypertension a Bone Marrow Disease?

Authors:  Kim Ramil C Montaniel; David G Harrison
Journal:  Circulation       Date:  2016-09-27       Impact factor: 29.690

5.  Genetic Interference With Endothelial PPAR-γ (Peroxisome Proliferator-Activated Receptor-γ) Augments Effects of Angiotensin II While Impairing Responses to Angiotensin 1-7.

Authors:  T Michael De Silva; Chunyan Hu; Dale A Kinzenbaw; Mary L Modrick; Curt D Sigmund; Frank M Faraci
Journal:  Hypertension       Date:  2017-07-03       Impact factor: 10.190

Review 6.  Endogenous hydrogen sulfide improves vascular remodeling through PPARδ/SOCS3 signaling.

Authors:  Danyang Tian; Xu Teng; Sheng Jin; Yuhong Chen; Hongmei Xue; Lin Xiao; Yuming Wu
Journal:  J Adv Res       Date:  2020-06-20       Impact factor: 10.479

7.  SOCS3 Gene Polymorphism and Hypertension Susceptibility in Chinese Population: A Two-Center Case-Control Study.

Authors:  Dabin Kuang; Lichen Dong; Lingyun Liu; Meiling Zuo; Yuanlin Xie; Taoming Li; Zhousheng Yang
Journal:  Biomed Res Int       Date:  2021-11-17       Impact factor: 3.411

Review 8.  Sulfide regulation of cardiovascular function in health and disease.

Authors:  Gopi K Kolluru; Rodney E Shackelford; Xinggui Shen; Paari Dominic; Christopher G Kevil
Journal:  Nat Rev Cardiol       Date:  2022-08-05       Impact factor: 49.421

9.  Interleukin 22 Promotes Blood Pressure Elevation and Endothelial Dysfunction in Angiotensin II-Treated Mice.

Authors:  Jing Ye; Qingwei Ji; Jianfang Liu; Ling Liu; Ying Huang; Ying Shi; Lei Shi; Menglong Wang; Mengling Liu; Ying Feng; Huimin Jiang; Yao Xu; Zhen Wang; Junlong Song; Yingzhong Lin; Jun Wan
Journal:  J Am Heart Assoc       Date:  2017-10-03       Impact factor: 5.501

10.  Interleukin-9 Deletion Relieves Vascular Dysfunction and Decreases Blood Pressure via the STAT3 Pathway in Angiotensin II-Treated Mice.

Authors:  Yunzhao Yang; Shaoqun Tang; Chunchun Zhai; Xin Zeng; Qingjian Liu; Cheng Xu; Hexiang Chen
Journal:  Mediators Inflamm       Date:  2020-02-14       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.